$ACOG shares saw big gain yesterday Alpha Cognition has announced the functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program.
Administration of the drug proved to reduce the extent of the functional deficit of TBI and improved functional recovery compared to untreated animals. The preclinical results, combined with clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI.
This is some really promising data coming from $ACOG. As shares saw an 8.6% gain yesterday on an increase in relative volume, I’m expecting this news to serve as a catalyst to push prices into some upward momentum.
We’ve seen shares test prices of $1.9 so fingers crossed we can see price action retest this resistance in the near future.
Shares of $ACOG.V are currently trading at $1.01 and the company is valued at $62.11 million.
https://ceo.ca/@businesswire/alpha-cognition-announce-data-from-pre-clinical-study